Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study

S Genevay, S Stingelin, C Gabay, S Genevay, S Stingelin, C Gabay

Abstract

Objectives: To explore the efficacy of a tumour necrosis factor alpha (TNFalpha) inhibitor (etanercept, Enbrel) in patients with severe sciatica.

Methods: A pilot study of etanercept was conducted in patients admitted to hospital for acute severe sciatica. Ten consecutive patients received three subcutaneous injections of etanercept (25 mg every 3 days) in addition to standard analgesia. Response was evaluated at day 10 (T1) and week 6 (T2) using a visual analogue scale for leg pain (VASL) and for low back pain (VASB), and two validated functional scores: the Oswestry disability index (ODI) and the Roland Morris disability questionnaire (RMDQ). The control group consisted of 10 patients with severe sciatica, who took part in an observational study on i.v. methylprednisolone.

Results: In the etanercept group all variables improved: VASB from 36 to 7; VASL from 74 to 12; RMDQ from 17.8 to 5.8, and ODI from 75.4 to 17.3; all p<0.001. Pain (VASL and VASB: p<0.001) and ODI (p<0.05) were significantly better in the etanercept group than in the methylprednisolone group.

Conclusion: In this open, historical group controlled study, patients with severe sciatica had sustained improvement after a short treatment with etanercept that was better than standard care plus a short course of methylprednisolone. These results suggest that inhibition of TNFalpha is beneficial in the treatment of sciatica and support a pathological role for TNFalpha in the pathogenesis of sciatica. These results need to be confirmed by a randomised controlled trial.

Figures

Figure 1
Figure 1
Percentage of improvement between T0 and T2. The length of the box plots represents the interquartile range; means and extremes are also given. 0% = no improvement, 100% total recovery. VASL, visual analogue scale for leg pain; ODI, Oswestry Disability Index; RMDQ, Roland Morris Disease Questionnaire.

References

    1. Spine (Phila Pa 1976). 2000 Dec 1;25(23):2975-80
    1. Semin Arthritis Rheum. 1998 Aug;28(1):60-71
    1. Eur Spine J. 2002 Apr;11(2):145-51
    1. Spine (Phila Pa 1976). 2002 May 1;27(9):911-7
    1. N Engl J Med. 2003 Feb 13;348(7):601-8
    1. Lancet Infect Dis. 2003 Mar;3(3):148-55
    1. Spine (Phila Pa 1976). 2003 Apr 15;28(8):750-3; discussion 753-4
    1. Spine (Phila Pa 1976). 2003 May 15;28(10):967-72
    1. Physiotherapy. 1980 Aug;66(8):271-3
    1. Spine (Phila Pa 1976). 1983 Mar;8(2):141-4
    1. Spine (Phila Pa 1976). 1984 Sep;9(6):549-51
    1. Spine (Phila Pa 1976). 1987 Apr;12(3):264-8
    1. Spine (Phila Pa 1976). 1993 Sep 1;18(11):1425-32
    1. Spine (Phila Pa 1976). 1995 Aug 15;20(16):1810-20
    1. Spine (Phila Pa 1976). 1996 Feb 15;21(4):411-4
    1. Spine (Phila Pa 1976). 1996 Feb 1;21(3):271-7
    1. Neuroreport. 1996 Nov 25;7(18):2897-901
    1. Spine (Phila Pa 1976). 1996 Dec 15;21(24):2820-5
    1. Spine (Phila Pa 1976). 2001 Apr 15;26(8):863-9

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться